Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 5/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952012 | 0.97 | HTR1A (0.44) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL4949576 | 0.97 | ADRA1D (0.45) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL4950274 | 0.96 | HTR1A (0.43) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL4945994 | 0.94 | HTR1A (0.46) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL4950532 | 0.93 | HTR1A (0.45) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL5172627 | 0.90 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL5172537 | 0.86 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL5475909 | 0.84 | HTR1A (0.41) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL4947383 | 0.83 | ADRA1D (0.47) | ADRA1DADRA1AHTR1ADRD2HTR2A | |
| SCHEMBL5461975 | 0.82 | HTR1A (0.46) | ADRA1DADRA1AADRA1BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | claimed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | ADRA1D 46/4885ADRA1A 152/4885ADRA1B 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.